DOCSLIB.ORG

University of Groningen the Pill and Thrombosis Van Vlijmen, Elizabeth

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
University of Groningen the Pill and Thrombosis Van Vlijmen, Elizabeth University of Groningen The pill and thrombosis van Vlijmen, Elizabeth Femma Willemien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 2016 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): van Vlijmen, E. F. W. (2016). The pill and thrombosis. Rijksuniversiteit Groningen. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license. More information can be found on the University of Groningen website: https://www.rug.nl/library/open-access/self-archiving-pure/taverne- amendment. Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 08-10-2021 Financial support for the printing of this thesis was kindly provided by the Dutch Medicines Evaluation Board and UMCG/GUIDE. ISBN: 978-90-367-8569-3 The Pill and Thrombosis ©2015 E. F. W. van Vlijmen ISBN: 978-90-367-8566-2 (printed version) ISBN: 978-90-367-8569-3 (digital version) All rights reserved. No part of this thesis may be reproduced, stored in retrieval center of any nature, or transmitted in any form or by any means without the written permission of the author. Cover design: Harry Zijderveld Cover painting: Lita Cabellut 2013© ‘Billy Holiday’ from the series ‘Strong women’ Layout: Harry Zijderveld - Graphic Design Printed by: drukkerij van Ark, Haren The Pill and thrombosis Proefschrift ter verkrijging van de graad van de doctor aan de Rijksuniversiteit Groningen op gezag van de rector magnificus prof. dr. E. Sterken en volgens besluit van het College voor Promoties. De openbare verdediging zal plaatsvinden op woensdag 17 februari 2016 om 14.30 uur door Elizabeth Femma Willemien van Vlijmen geboren op 5 februari 1958 te Naarden Promotores Prof. Dr. Karina Meijer Prof. Dr. J. C. Kluin-Nelemans Co-promotor Dr. N.J.G.M. Veeger Beoordelingscommissie Prof. Dr. M. V. Huisman Prof. Dr. F. R. Rosendaal Prof. Dr. S. A. Scherjon Paranimfen: Clarissa van Vlijmen-van Keulen Annemarie van Leijsen-de Vries Voor mijn ouders TABLE OF CONTENTS Chapter 1 9 General introduction and outline of thesis Chapter 2 41 Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects Archives of Internal Medicine 2007;167:282-289 Chapter 3 59 Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or Prothrombin mutation: a rational approach to contraception Blood 2011;118:2055-2061 Chapter 4 79 Combined hormonal contraceptives, thrombophilia and the risk of venous thromboembolism: a systematic review and meta-analysis Submitted Chapter 5 101 A male or female family history of VTE: does it influence hormone-related VTE risk? Submitted Chapter 6 117 Clinical profile and recurrence rate in women with venous thromboembolism during combined hormonal contraceptive use: results of a prospective cohort study British Journal of Hematology 2015;DOI 10.1111/bjh.13534 Chapter 7 127 Summary, discussion and future perspectives Chapter 8 157 Nederlandse samenvatting Chapter 9 173 Dankwoord Chapter1 General introduction and outline of thesis Introduction Chapter 1 Introduction Combined oral contraceptives and venous thromboembolism The combined oral contraceptive, i.e. the ‘Pill’, was the first medicinal product developed that had to be taken every day on a regular basis by persons not suffe- ring from any disease. Today, world-wide more than 100 million women start the day with taking the ‘Pill’.1 Although the Pill is a safe and highly effective contracep- tive method in the vast majority of women, in a small group of women its use is associated with a rare but potentially serious adverse event, i.e. venous throm- boembolism (VTE). Up to now, this association has been the topic of many studies, including the studies presented in this thesis, and probably there are many more to follow, as even after the recent 50th anniversary of the Pill this risk still has not been solved. Combined oral contraceptives Composition Combined oral contraceptives (COCs) contain a combination of a synthetic estro- gen and a synthetic progestogen. The estrogen component is ethinylestradiol and recently also estradiol, but there are many different types of synthetic proges- togens, e.g. levonorgestrel, norethisterone, desogestrel, gestodene, dienogest, drospirenone, norgestimate, etonogestrel, norelgestromin, nomegestrol, chlor- madinone, and cyproterone. Initially, the dose of ethinylestradiol was up to 150 micrograms, but since the early seventies the dose is steadily lowered to 35-15 micrograms (so-called sub-50 Pills) that are used today. Also the progestogen doses have decreased substantially. Further, currently several COCs have standard and low-dose versions. Additionally, there are not only oral combined contraceptives, but also non-oral preparations such as a vaginal ring to be applied once a month and a patch to be applied once weekly. 11 Introduction The reason why there are so many synthetic progestogens is that the initially deve- loped progestagens, besides the desired progestogenic effects, also had androge- nic effects. Androgenic properties could result in androgenic side effects like acne, hirsutism, and negative effects on the lipid metabolism. Development therefore focused on progestagens having less androgenic properties. The consecutive development of new COCs, i.e. with a new synthetic proges- togen, is divided into ‘generations‘, and is related to the time point of their market launch. ‘First generation’ is related to the very first COCs, which were approved around 1960. An overview of several generations of COCs with different synthetic progestogens and their first date of introduction is given in Table 1. Table 1. Combined hormonal contraceptives divided into generations Type of progestogen Generation Market introduction Ethinylestradiol/norethisterone-containing COC (Modicon©) 1st generation 1960 Ethinylestradiol/levonorgestrel-containing COC (Microgynon 30©) 2nd generation 1974 Ethinylestradiol/norgestimate-containing COC (Cilest©) 2nd generation 1990 Ethinylestradiol/desogestrel-containing COC (Marvelon©) 3rd generation 1984 Ethinylestradiol/gestodene-containing COC (Femodeen©) 3rd generation 1984 Ethinylestradiol/cyproterone-containing COC (Diane 35©) 4th generation 1987 Ethinylestradiol/chlormadinone-containing COC (Madinelle©)a 4th generation 1995 Ethinylestradiol/drospirenone-containing COC (Yasmin©) 4th generation 2000 Ethinylestradiol/etonogestrel-containing vaginal ring (NuvaRing©) 4th generation 2001 Ethinylestradiol/norelgestromin-containing patch (Evra©) 4th generation 2002 Estradiol/dienogest-containing COC (Qlaira©) ‘5th’ generation 2008 Estradiol/nomegestrol-containing COC (Zoely©) ‘5th’ generation 2011 a: ethinylestradiol/chlormadinone-containing COCs are not available in NL However, as there are now many different preparations, it is suggested not to use these terms any longer, as they lead to confusion. In practice this has already resulted in studies on COCs and thromboembolism with e.g. COCs being catego- 12 Introduction rized as a ‘3rd generation’, ‘4th generation’ or as a ‘2nd generation’, which makes- the interpretation of clinical results for the individual progestogens such as risk of VTE, challenging.2 History of combined hormonal contraceptives Around 1920, several Austrian scientists demonstrated the occurrence of tempo- rary contraception by transplantation of ovaries of a pregnant animal into a non- pregnant animal. These experiments were followed by studies in mice showing that extracts of ovaries could inhibit ovulation. These first studies were performed by Ludwig Haberlandt, an Austrian professor of physiology. He is seen as the Grandfather of the ‘Pill’, as he was the first to perform experiments with the goal to obtain contraception by using female sex hormones. His aim was to develop hormonal contraception by mimicking a pregnant state, which would create a ‘temporary hormonal sterilization’. In 1931, he started the production of a hormo- nal extract ‘Infecundin’ in co-operation with the Hungarian pharmaceutical com- pany Gedeon-Richter. However, he was severely criticized by his colleagues and in the lay public press, who accused him of hindering the unborn life. Despite all opposition, he started the first clinical trials. Unfortunately, he died at an early age and his co-worker Otto Fellner lost his life during World War II, which brought an end to this first initiative.3,4 Although Gabriel Fallopinus already in 1561 mentioned the existence of a ‘corpus luteum’, of which the structure is described by the Dutch anatomist Volcher Coiter in 1573,5 its function in regulating the menstrual cycle remained unknown for long. Only at the end of the nineteenth
Load more

Recommended publications
  • Efficacy of a Selective Estrogen Receptor Modulator: 'Ormeloxifene' in Management of Dysfunctional Uterine Bleeding
    JSAFOG CLINICALEfficacy PRACTICEof a Selective Estrogen Receptor Modulator: ‘Ormeloxifene’ in Management of Dysfunctional Uterine Bleeding Efficacy of a Selective Estrogen Receptor Modulator: ‘Ormeloxifene’ in Management of Dysfunctional Uterine Bleeding 1Tapan Kumar Bhattacharyya, 2Anusyua Banerji 1Professor and Head, Department of Obstetrics and Gynecology, SRMS Institute of Medical Sciences, Bareilly, Uttar Pradesh India 2Senior Resident, RG Kar Medical College, Kolkata, West Bengal, India Correspondence: Tapan Kumar Bhattacharyya, Professor and Head, Department of Obstetrics and Gynecology, SRMS Institute of Medical Sciences, Bareilly-243202, Uttar Pradesh, India, Phone: 09748236960, e-mail: [email protected] Abstract Background: Ormeloxifene, a third generation selective estrogen receptor modulator, has been claimed to ameliorate symptoms of DUB. This study was undertaken to compare the efficacy of ormeloxifene and norethisterone. Methods: 180 cases of DUB, who have completed child bearing and are above 35 years, were randomly assigned ormeloxifene, progesterone and iron groups. Ormeloxifene group received ormeloxifene for 12 weeks. Norethisterone group received norethisterone for 12 days in every cycle for six cycles. Iron was given as 60 mg of elemental iron daily. Before starting drug therapy, ultrasound, office hysteroscopy and endometrium sampling for histopathology was obtained and repeated at end of follow-up. The side effects and complications of drug ormeloxifene were noted and relief of symptoms and patient acceptability were compared with norethisterone. Results: 81.7% in the ormeloxifene administered subjects marked relief of symptoms with significant reduction of PBAC scores, reduction of blood clots, and rise in hemoglobin levels. Side effects/complications included amenorrhea, urinary incontinence and genital prolapse. The ease of administration of ormeloxifene facilitated compliance and acceptability.
    [Show full text]
  • Schwerpunkt 40 Jahre Pille
    Familienplanungs- RUNDBRIEF Ausgabe Juni 2000 Nr. 1/2 Inhalt Einleitung 3 Hormonelle Kontrazeption: 40 Jahre Pille 4 – Entwicklungen, die zur Herstellung der Pille führten 4 – Weiterentwicklung der Pille von 1960 bis heute 8 – Die gesellschaftspolitische Bedeutung der Pille 12 – Hormonelle Kontrazeptiva heute in Deutschland 14 – Anwendung der hormonalen Kontrazeptiva nach dem heutigen 17 Wissensstand – Wechselwirkungen 24 Anhang (Ende des Dokuments) – Medikamente, die die Sicherheit A1 der Pille beeinträchtigen können – Liste hormonaler Kontrazeptiva A2 IPPF Informationen – Gestagen-Implantate 27 Forum – Vorgeburtliche Untersuchungen: 28 Möglichkeiten und Grenzen Veranstaltungskalender 29 Stichwortverzeichnis 1999 31 Deutsche Gesellschaft für Familienplanung, Sexualpädagogik und Sexualberatung e.V., Bundesverband e.V., Sexualberatung und Sexualpädagogik für Familienplanung, Gesellschaft Deutsche Stresemannallee 3, 60596 Frankfurt am Main, Telefon 069/639002 Impressum: 2000 Herausgeber: PRO FAMILIA-Bundesverband Redaktion: Dr. med. Ruth Eichmann, Frankfurt am Main Dr. med. Ines Thonke, Frankfurt am Main Dr. med. Jutta Walter, Heidelberg Anschrift: PRO FAMILIA-Bundesverband Stresemannallee 3 60596 Frankfurt am Main Gefördert von der Bundeszentrale für gesundheitliche Aufklärung (BZgA). Familienplanungs- RUNDBRIEF Juni 2000 Nr. 1/2 3 In der Rubrik „HINWEISE“ wird wie üblich in dem Einleitung jeweiligen Familienplanungs-Rundbrief Aktuelles aus der Medizin zu finden sein, das von besonde- rer Bedeutung für die Beratungspraxis ist. Lite- raturneuerscheinungen und Ankündigungen von Veranstaltungen runden die einzelnen Familien- planungs-Rundbriefe ab. In Übereinstimmung mit der gewohnten Gliede- rung befasst sich der erste Familienplanungs- Beibehalten wird ferner der Abschnitt, in welchem Rundbrief des Jahres mit einer Vorschau auf die aktuelle Informationen der IPPF (International im laufenden Jahr geplanten Schwerpunktthe- Planned Parenthood Federation) aufgenommen men. Dafür vorgesehen sind: werden, soweit sie medizinischen Inhalts sind.
    [Show full text]
  • Efficacy of Ormeloxifene in Management of Dysfunctional Uterine Bleeding
    Online - 2455-3891 Vol 11, Issue 11, 2018 Print - 0974-2441 Research Article EFFICACY OF ORMELOXIFENE IN MANAGEMENT OF DYSFUNCTIONAL UTERINE BLEEDING UMESH SAWARKAR1, SARANG DESHMUKH2*, ASHWINI RAUT3, UMA BHOSALE4, ASHOK SHENOY K5 1Department of Obstetrics and Gynaecology, Dr. Panjabrao Deshmukh Memorial Medical College, Amravati, Maharashtra, India. 2Department of Pharmacology, Smt. Kashibai Navale Medical College, Pune, Maharashtra, India. 3Medical officer, District General Hospital, Amravati, Maharashtra, India. 4Department of Pharmacology, Smt. Kashibai Navale Medical College, Pune, Maharashtra, India. 5Department of Pharmacology, Kasturba Medical College, Manipal Academy of Higher Education, Mangalore, Karnataka, India. Email: [email protected] Received: 11 June 2018, Revised and Accepted: 05 July 2018 ABSTRACT Objective: The objective was to evaluate the efficacy of ormeloxifene in dysfunctional uterine bleeding (DUB) with respect to bleeding pattern and improvement in hemoglobin (Hb). Methods: This was an interventional study on 99 patients of DUB visiting the gynecology outpatient department over 1 year using semi-structured pro forma. After voluntary participation of patients, tablet ormeloxifene was given at the dose of 30 mg biweekly for 2 months. In case of a therapeutic response as informed by the patient, the dose was reduced to 30 mg weekly for a further period of 4 months. All patients were treated for 6 months. Type, amount, and duration of bleeding, frequency of menstrual cycle, passage of clots, and impact on Hb were assessed. Result and Observations: Menorrhagia was the main type of bleeding. 36–40 years of age group was the most common. After the intervention, 76.8% of women achieved a duration of bleeding of 4–5 days, and in 87% of women, menstrual cycle became regular.
    [Show full text]
  • Methods of Contraception
    International Journal of Science and Research (IJSR) ISSN: 2319-7064 ResearchGate Impact Factor (2018): 0.28 | SJIF (2018): 7.426 Methods of Contraception Dr. Manish Adhia1, Anushka Agrawal2, Riana Caeiro3, Param Desai4, Vishwa Naik5 1Associate Professor (B.Sc. Microbiology, MMS) 2, 3, 4, 5Students, MBA Pharma Tech (Sem VII, IV Year), NMIMS, Mumbai, Maharashtra, India Abstract: Contraception is the process of preventing pregnancy by various methods. This paper focuses on different kinds of methods of contraception used in India along with their advantages and disadvantages. As India being a diverse country and has certain beliefs in myths since ages, there is a direct impact on the pschycological behaviour or attitude towards using contraceptives found even today. From this research we would like to draw the opinions of the gyneachologists and finding out which is the best contraceptive method and what all are the difference of opinions between the doctors and the consumers regarding the same. Hence, we had also focused on the most commonly used contraceptives in India and further, we will be conducting a survey which will let us know that which contraceptives are in most demand in the market. It was also studied that how geographic and demographic behaviour affect consumer buying behavior when it comes to contraceptives. Keywords: methods of contraception, pshycologiacal attitude towards contraceptives, difference of opinions between doctors and consumers 1. Introduction like IUD’s, Pills and condoms have been available in most of the developed and developing countries. Now there is a India being an over populated country benefits a lot from huge amount of advancement consisting of newer different methods of contraception.
    [Show full text]
  • Cleaning up After Sex: an Environmental History of Contraceptives in the United States, 1873—2010 Sarah Ruth Payne
    University of New Mexico UNM Digital Repository History ETDs Electronic Theses and Dissertations 9-3-2010 Cleaning Up After Sex: An Environmental History of Contraceptives in the United States, 1873—2010 Sarah Ruth Payne Follow this and additional works at: https://digitalrepository.unm.edu/hist_etds Recommended Citation Payne, Sarah Ruth. "Cleaning Up After Sex: An Environmental History of Contraceptives in the United States, 1873—2010." (2010). https://digitalrepository.unm.edu/hist_etds/62 This Dissertation is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been accepted for inclusion in History ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact [email protected]. CLEANING UP AFTER SEX: AN ENVIRONMENTAL HISTORY OF CONTRACEPTIVES IN THE UNITED STATES, 1873–2010 BY SARAH R. PAYNE B.A., History, Nebraska Wesleyan University, 1997 M.A., History, University of Wyoming, 2001 DISSERTATION Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy History The University of New Mexico Albuquerque, New Mexico August, 2010 ACKNOWLEDGMENTS My heartfelt thanks go first and foremost to Dr. Virginia Scharff. For her encouragement, insight, and patience, with the dissertation and with life in general, I am truly grateful. Dr. Scharff’s skills as a researcher and writer are matched by her skills as a mentor, which have made possible the quality work of so many of her graduate students. I also thank Dr. Scharff and her Center for the Southwest for providing me funding and experience organizing lectures and workshops, and allowing me to work with so many wonderful scholars.
    [Show full text]
  • Hormones and the Female Voice: an Exploration of the Female Hormonal Cycle from Puberty to Menopause and How It Affects the Vocal Apparatus
    HORMONES AND THE FEMALE VOICE: AN EXPLORATION OF THE FEMALE HORMONAL CYCLE FROM PUBERTY TO MENOPAUSE AND HOW IT AFFECTS THE VOCAL APPARATUS A Dissertation Submitted to the Temple University Graduate Board In Partial Fulfillment of the Requirements for the Degree DOCTOR OF MUSICAL ARTS by Patricia Vigil July 2015 Examining Committee Members: Dr. Christine Anderson, Advisory Chair, Department of Voice and Opera Dr. Rollo Dilworth, Department of Music Education and Therapy Dr. Lawrence Indik, Department of Voice and Opera Dr. Joyce Lindorff, Department of Keyboard Studies © Copyright 2015 by Patricia Vigil All Rights Reserved ABSTRACT The purpose of this paper is to examine the female hormonal cycle throughout a woman’s life and its effects on the singing voice. Dealing with vocal issues brought on by hormonal fluctuations can be extremely frustrating for the professional singer, as these issues can wreak havoc on performance and practice schedules. The best weapon of defense against its unpredictability is information. Unfortunately, data on the female hormonal cycle and its effects on the voice is not covered in most standard vocal pedagogy books. Information on the subject is often relegated to a small section of a chapter, and even then usually describes only the symptoms: edema, hoarseness, and loss of high notes and power. The question as to why these symptoms happen every month and during menopause, and whether there is anything that can be done to alleviate them, remains largely unanswered. A candid discourse on the subject of hormones and the female voice has begun, but now must brought into the open.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • International Journal of Research in Pharmaceutical Sciences
    Muddala Vara Prasanna Rao et al., Int. J. Res. Pharm. Sci., 2020, 11(4), 5678-5684 ORIGINAL ARTICLE INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACEUTICAL SCIENCES Published by JK Welfare & Pharmascope Foundation Journal Home Page: www.pharmascope.org/ijrps Comparative Study of Desogestrel- Containing Oral Contraceptive and Levonorgestrel- Containing Oral Contraceptive in Dysfunctional Uterine Bleeding Swathi Suresh, Mariya Els Johny, Kiruba Shankari, Ahamed Irshath U, Yokesh M, Muddala Vara Prasanna Rao* Department of Pharmacy Practice, School of Pharmaceutical Sciences, Vels Institute of Science, Technology and Advanced Studies (VISTAS), Pallavaram, Chennai, Tamil Nadu, India Article History: ABSTRACT Received on: 25 May 2020 Dysfunctional uterine bleeding is a type of abnormal uterine bleeding where Revised on: 25 Jul 2020 vaginal bleeding occurs outside of the menstrual cycle in the absence of any Accepted on: 26 Jul 2020 known pelvic pathology. Dysfunctional uterine bleeding can be treated safely with hormone therapy. Combined oral contraceptives help in increased men- Keywords: strual cycle regularity and decreased blood loss. In this study, a reliable drug for the dysfunctional uterine bleeding with maximum effectiveness and mini- Combined Oral mal side effects were assessed. This study was conducted on 120 cases of dys- Contraceptives, functional uterine bleeding. Patients who were diagnosed with dysfunctional Dysfunctional Uterine uterine bleeding were randomly assigned into two groups. Group D and group Bleeding, L included patients who were given Ethinyl estradiol 0.02mg + desogestrel Menstrual Blood Loss, 0.15mg and Ethinyl estradiol 0.03mg + levonorgestrel 0.15mg respectively for Pictorial Blood the four consecutive 28- day cycles. Menstrual blood loss was assessed using Assessment Chart the pictorial blood assessment chart (PBAC) score on 2nd and 4th months of recruitment.
    [Show full text]
  • Journal of Pharmacology and Toxicological Studies
    e-ISSN: 2322-0139 p-ISSN: 2322-0120 Research & Reviews: Journal of Pharmacology and Toxicological Studies Long-Term Utilization of Hormonal Contraceptives: Leads to Danger of an Uncommon Cerebrum Tumour * Shalini K Bharat institute of pharmacy, JNTUH, Hyderabad Short Communication Received: 15/05/2015 *For Correspondence: Revised: 21/05/2015 Shalini K, Bharat institute of pharmacy, JNTUH, Hyderabad, E-mail: Accepted: 02/06/2015 [email protected] Keywords: Contraceptives, Progestogen, Progestin, Hormones Introduction Hormonal contraception alludes to anticonception medication routines that follow up on the endocrine framework. All techniques are made out of steroid hormones, albeit in India one specific estrogen receptor modulator is showcased as a prophylactic. Hormonal contraception alludes to anticonception medication techniques that follow up on the endocrine framework. All systems are made out of steroid hormones, albeit in India one specific estrogen receptor modulator is promoted as a preventative. The first hormonal technique the consolidated oral preventative pill—was initially showcased as a prophylactic in 1960. In the following decades numerous other conveyance techniques have been created, despite the fact that the oral and injectable systems are by a wide margin the most prominent. By and large, 18% of the world's preventative clients depend on hormonal methods. Hormonal contraception is profoundly successful: when tackled the recommended calendar, clients of steroid hormone systems experience pregnancy rates of less than 1% every year. Immaculate utilization pregnancy rates for most hormonal contraceptives are typically around the 0.3% rate or less. Currently accessible systems must be utilized by ladies; the improvement of a male hormonal prophylactic is a dynamic examination range.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • Role of Ormeloxifene in Management of Abnormal Uterine Bleeding
    DOI: 10.21276/sjams.2017.5.3.21 Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online) Sch. J. App. Med. Sci., 2017; 5(3B):796-799 ISSN 2347-954X (Print) ©Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com Original Research Article Role of Ormeloxifene in Management of Abnormal Uterine Bleeding Soniya Prerna1, Verma Asha2, Verma Kusum3, Gupta Richa4, Sharma Bhoomika5 1Junior Resident, 2Professor, 3Assistant Professor, 4Senior resident, 5Junior Resident Department of Obstetrics and Gynecology, S.M.S. Medical College, Jaipur (Rajasthan), India *Corresponding author Soniya Prerna Email: [email protected] Abstract: The objective is to study the efficacy, safety and acceptability of ormeloxifene in the medical management of AUB. This is a Hospital based interventional study which included a sample size of 52 Samples. 52 cases of AUB were recruited. Each was given 60 mg of ormeloxifene twice weekly for 3 months and then once a week for next month. Follow up was done at 1,3 and 4 month. Primary outcome measures were menstrual blood loss, haemoglobin concentration and endometrial thickness. Secondary outcome measures were the acceptability and side effects of ormeloxifene. The mean pretreatment HB concentration was significantly increased and means pretreatment endometrial thickness was reduced. Thus ormeloxifene is safe and effective drug for medical management of AUB. It is non- steroidal, pharmacologically and metabolically safe oncologically protective and cost effective too. Keywords: ormeloxifene, AUB, HB INTRODUCTION easier to conduct, but are expensive [4]. Various drugs Menorrhagia is usually defined as menstrual used are NSAIDS, tranexamic acid, Hemostatic blood loss of >80 ml/cycle or a PBAC score (pictorial progestins, oral contraceptives, Antifibrinolytics, blood loss assessment chart) of >100 [1].
    [Show full text]
  • AOGD Bulletin November 2019.Indd
    AOGDAOGD BULLETINBULLETIN Volume 19 I November 2019 I Monthly Issue 7 I Price `30 Only Enlightening the Path for Next Generation of Gynaecologists Dedicated Issue: Contraception AAOGDOGD SSECRETARIATECRETARIAT Department of Obstetrics & Gynaecology, 3076, Teaching Block, IIIrd Floor, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029 Vol.19, No.7; November,Tel.: 2019 011-26546603, 26593221 E-mail: [email protected] 1 Website: www.aogd.org 2 AOGD Bulletin AOGD Bulletin Volume 19 • Monthly Issue 7 • November 2019 AOGD Executive Committee 2019-20 President Vice President Hon. Secretary Dr Sunesh Kumar Dr Ashok Kumar Dr Vatsla Dadhwal President Patrons Dr Sunesh Kumar Dr D Takkar Dr Kamal Buckshee Vice President Dr Neera Agarwal Dr Ashok Kumar Dr Sheila Mehra Hony. Secretary Dr S K Bhandari Contents Dr Vatsla Dadhwal Dr S N Mukherjee Dr Swaraj Batra • Oral Contraceptive Pills (OCPs) 7 Scientifi c Advisors Dr Urmil Sharma Dr Dipika Deka Dr V L Bhargava Swati Agrawal, Dr Anu Handa Dr Neerja Bhatla Dr K K Roy Advisors • Non-Oral Hormonal Contraceptive Methods 11 Dr Neena Malhotra Dr Alka Kriplani Dr Amita Suneja Jyoti Meena, Garima Patel Treasurer Dr Chitra Raghunandan Dr Rohini Sehgal Dr Pratima Mittal • Intrauterine Devices 15 Dr SB Khanna Editor J B Sharma, Rinchen Zangmo Dr Sharda Jain Dr J B Sharma Dr Shubha Sagar Trivedi • PPIUCD: An Effective Method of Postpartum Contraception 21 Web Editor Dr Sudha Salhan Dr Juhi Bharti Dr Suneeta Mittal Monika Gupta, Sunita Malik, Harshita Dr Usha Manaktala Joint Secretaries
    [Show full text]